Global prevalence of human papillomavirus-driven oropharyngeal squamous cell carcinoma following the ASCO guidelines: A systematic review and meta-analysis

Author(s):Show less -

Linhares Almeida Mariz, Bruno Augusto ^[1] ; Kowalski, Luiz Paulo ^{[2, 3]} ; William Jr, William Nassib ; de Castro, Gilberto ^[4] ; Freitas Chaves, Aline Lauda ^[5] ; Santos, Marcos ^[6] ; de Oliveira, Thiago Bueno ^[7] ; Damaceno Araujo, Anna Luiza ^[1] ; Costa Normando, Ana Gabriela ^[1] ; Prado Ribeiro, Ana Carolina ^{[1, 8]} ; Brandao, Thais Bianca ^{[8, 9]} ; Vargas, Pablo Agustin ^[1] ; Lopes, Marcio Ajudarte ^[1] ; Santos-Silva, Alan Roger ^[1] ; Gr, Latin Amer Cooperative Oncology ; Canc, Brazilian Grp Head Neck

Affiliation

^[1] Univ Estadual Campinas, Piracicaba Dent Sch, Oral Diag Dept, UNICAMP, Piracicaba - Brazil

^[2] Univ Sao Paulo, AC Camargo Canc Ctr, Head & Neck Surg Dept, Med Sch, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Dept Head & Neck Surg, Med Sch, Sao Paulo - Brazil

^[4] Sao Paulo State Canc Inst ICESP FMUSP, Dept Clin Oncol, Sao Paulo - Brazil

^[5] DOM Oncol Grp, Divinopolis - Brazil

^[6] Brasilia Univ, UNESCO Chair Bioeth, Brasilia, DF - Brazil

^[7] AC Camargo Canc Ctr, Med Oncol Dept, Sao Paulo, SP - Brazil

^[8] Sao Paulo State Canc Inst ICESP FMUSP, Dent Oncol Serv, Sao Paulo, SP - Brazil

^[9] Hosp Sirio Libanes, Oral Med Dept, Sao Paulo - Brazil

• Document type: Review article
• Source: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY; v. 156, DEC 2020.
• Web of Science Citations: 0

Abstract

Objectives: to provide accurate information about the global prevalence of human papillomavirus (HPV) in oropharyngeal squamous cell carcinomas (OPSCC). Material and methods: a systematic review was performed using three main electronic databases. Studies were independently assessed by two reviewers based on established eligibility criteria, to identify the prevalence of HPV-driven OPSCC following criteria defined by the American Society of Clinical Oncology. Risk of bias was assessed using the Joanna Briggs Institute Critical Appraisal Checklist. Statistical software MedCalc was used to perform meta-analyses. Results: from 2215 records found, 15 were included, reporting data from 6009 patients (time period range: 1980-2016), distributed in 11 countries. Eleven studies were considered as presenting low risk, and four as moderate risk of bias. Using proportion meta-analysis, pooled prevalence of HPV-driven OPSCC was 44.8 % (95 %CI: 36.4-53.5 %; i(2) = 97.6 %), with the highest rates in New Zealand (74.5 %; 95 %CI: 60.9-85.3 %), and the lowest in Brazil (11.1 %; 95 %CI: 4.5-21.5 %). HPV prevalence was similar between males (45.7 %; 95 %CI: 36.5-55.0 %; i(2) = 96.4 %) and females (42.2 %; 95 %CI: 34.3- 50.5 %; i(2) = 85.4 %). Mean/median age ranged from 59.1-67.1 years in the HPV-negative group, and from 55.7-63.5 years in the HPV-positive group. There was an overall discordance between testing by p16 (49.4 %; 95 %CI, 38.2-60.5 %; i(2) = 96.2 %) and p16+ISH/PCR (44.7 %; 95 %CI, 33.5-56.2 %; i(2) = 96.4 %). Conclusion: Overall pooled prevalence of HPV-driven OPSCC was approximately 45 %, with similar distribution among males and females. Double p16/HPV-DNA/RNA testing may be considered to increase specificity and prognostic accuracy. (AU)

• FAPESP's process: 18/24715-2 - FGF-2, FGFR-1, PI3K, Akt and COX-2 expression in Oral Leucoplakia, primary and metastatic Oral Squamous Cell Carcinoma
• Grantee: Bruno Augusto Linhares Almeida Mariz
• Support Opportunities: Scholarships in Brazil - Doctorate